N/A
N=300
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Androgenetic Alopecia · Coronavirus Disease 2019 · Covid19 · Male Pattern Baldness · Female Pattern Baldness
Bottom Line
View on ClinicalTrials.gov: NCT04898166 ↗Enrolled (actual)
300
Serious AEs
100.0%
Results posted
Aug 2021
Primary outcome: Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Syeda Mahanum Ali
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Androgenetic Alopecia Frequency in Participants. |
209; 37; 11; 43 | — |
| PRIMARY Severity of Androgenetic Alopecia in Patients |
43; 9; 177; 28 | — |
| PRIMARY 300 Participants Mean Age |
53.06 | — |
| PRIMARY Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group. |
15; 10; 13; 18; 13; 0 | — |
| PRIMARY Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males |
20; 52; 14; 27; 5; 25 | 0.000 sig |
| PRIMARY Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females |
9; 3; 4; 17; 3; 8 | 0.081 |
| PRIMARY Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females. |
0; 4; 7; 5; 00; 00 | — |
| PRIMARY Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males |
4; 11; 10; 27; 6; 14 | — |
| PRIMARY Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females |
41; 28; 72; 16; 30; 26 | — |
| SECONDARY Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants |
29; 6; 4; 12; 15; 8 | — |
| SECONDARY Disease Duration of COVID-19 |
11.79 | — |
Summary
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.
Eligibility Criteria
Inclusion Criteria
- Hospitalized patients of diagnosed covid-19 age > 20years
- with or without androgenetic alopecia
- with or without comorbidities
- irrespective of disease duration -
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT04898166). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.